Is prevention of stone recurrence financially worthwhile?

Urological Research

Volumn 34, Issue 2, 2006, Pages 157-161

  Robertson, W G ^a  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

Author keywords

Cost; Extracorporeal shockwave lithotripsy; Open surgery; Percutaneous nephrolithotomy; Stone recurrence

Indexed keywords

ALKALI; ALLOPURINOL; ANTIBIOTIC AGENT; BENDROFLUMETHIAZIDE; CELLULOSE PHOSPHATE; CITRATE POTASSIUM; CORTICOSTEROID; MAGNESIUM; PENICILLAMINE; PHOSPHATE; POTASSIUM; PYRIDOXINE; THIAZIDE DIURETIC AGENT; TIOPRONIN; VITAMIN D;

CONFERENCE PAPER; COST CONTROL; DRUG COST; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; LIFESTYLE; METABOLISM; MINIMALLY INVASIVE SURGERY; NEPHROLITHIASIS; NUTRITION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; RISK FACTOR; SCREENING; UNITED KINGDOM;

CALCIUM; CELLULOSE; DISEASE MANAGEMENT; HUMANS; KIDNEY CALCULI; RECURRENCE;

EID: 33645212266     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-005-0030-4     Document Type: Conference Paper

References (15)

1. Robertson WG (1993) Urinary tract calculi. In: Nordin BEC, Need AG, Morris (eds) Metabolic bone and stone disease, 3rd edn. Churchill Livingstone, Edinburgh, pp 249-311
2. Pearle MS, Clayman RV (1996) Outcomes and selection of surgical therapies of stones in the kidney and ureter. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones - medical and surgical management. Lippincott-Raven, Philadelphia, pp 709-755
3. Williams RE (1963) Long-term survey of 538 patients with upper urinary tract stone. Br J Urol 35:416-437
4. Parks JH, Coe FL (1996) The financial effects of kidney stone prevention. Kidney Int 50:1706-1712
5. Pearle MS, Calhoun EA, Curhan GC (2005) Urologic diseases in America project: urolithiasis. J Urol 173:848-857
6. Robertson WG (1998) Medical management of urinary stone disease. Europ Urol Update Series 6:139-144
7. Strohmaier WL (2000) Volkswirtschaftliche Aspekte des Harnsteinleidens und der Harnsteinmetaphylaxe. Urologe A 39:166-170
8. Chandhoke PS (2005) When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol 168:937-940
9. Robertson WG (2003) A risk factor model of stone-formation. Front Biosci 8:1330-1338
10. Coe FL, Parks JH, Asplin JR (1992) The pathogenesis and treatment of kidney stones - medical progress. N Engl J Med 327:1141-1152
11. Fine JK, Pak CYC, Preminger GM (1995) Effect of medical management and residual fragments on recurrent stone formation following shock wave lithotripsy. J Urol 153:27-33
12. Pak CYC (1998) Kidney stones. Lancet 351:1797-1801
13. Rodman JS, Seidman C, Jones R (1996) No more kidney stones. Wiley, New York
14. Norman RW, Bath SS, Robertson WG, Peacock M (1984) When should patients with symptomatic stone disease be evaluated metabolically? J Urol 132:1137-1139
15. Robertson WG (2000) Is it possible to motivate patients with recurrent stones to adhere to their treatment regimen? In: Rodgers AL, Hibbert BE, Hess B, Khan SR, Preminger GM (eds) Urolithiasis 2000. University of Cape Town Press, Cape Town, pp 624-627